Osteoporosis  >>  risedronate delayed-release  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
risedronate delayed-release / Generic mfg.
FACT, NCT00092014: A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)

Completed
3
1053
NA
Alendronate, MK-0217, FOSAMAX®, Risedronate 35 mg, Actonel®, Atelvia®, Elemental Calcium, Vitamin D, Risendronate placebo, Alendronate placebo
Organon and Co
Postmenopausal Osteoporosis
04/04
04/04
NCT00846196: A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

Completed
3
538
US
risedronate DR (Phase III clinical supply), Phase III clinical supply, risedronate 35 mg DR (Commercial Tablet), Commercial Tablet
Warner Chilcott, Sanofi
Osteoporosis
05/09
05/09
NCT00541658 / 2007-001521-98: A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Completed
3
923
US, Canada, Europe, RoW
risedronate, IRBB, DRFB, DRBB
Warner Chilcott
Postmenopausal Osteoporosis
04/10
04/10
WE RISE U01, NCT04922333: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

Recruiting
3
200
US
Risedronate, Actonel, Atelvia, Placebo
Wake Forest University Health Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Bone Loss
04/27
04/27

Download Options